Efficacy of Esketamine for Patients With Irritable Bowel Syndrome | MicrobiomeTrials← Back to trialsNCT06788444
Efficacy of Esketamine for Patients With Irritable Bowel Syndrome
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2025-02-08Est. Completion: 2026-12-31
Enrollment target: 552 participants Locations- Beijing Tiantan Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
IBS (Irritable Bowel Syndrome)
Study evaluating the effect of UCB8600 on mast cell activation in the human gut:
IBS is a disease characterized by abdo…
Leuven, BelgiumEst. completion Oct 2027
Disorders of Gut-brain InteractionLifestyle and Dietary InterventionsGastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder, with around 80% of patients experiencing n…
Hualien City, TaiwanEst. completion Dec 31, 2026
Recruiting
Some people living with long-term physical health conditions report feeling dismissed, disbelieved, or not taken serious…
London, United KingdomEst. completion Mar 1, 2027